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Abstract 1 
 2 
Recent developments in automated optical sectioning microscope systems have 3 
enabled researchers to conduct high resolution, three-dimensional (3D) microscopy at 4 
the scale of millimeters in various types of tissues. This powerful technology allows the 5 
exploration of tissues at an unprecedented level of detail, while preserving the spatial 6 
context. By doing so, such technology will also enable researchers to explore cellular 7 
and molecular signatures within tissue and correlate with disease course. This will allow 8 
an improved understanding of pathophysiology and facilitate a precision medicine 9 
approach to assess the response to treatment. The ability to perform large-scale 10 
imaging in 3D cannot be realized without the widespread availability of accessible 11 
quantitative analysis. In this review, we will outline recent advances in large-scale 3D 12 
imaging, and discuss the available methodologies to perform meaningful analysis and 13 
potential applications in translational research.  14 
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Introduction 1 
The diagnostic approach to human disease frequently relies on a pathological 2 
assessment of a biopsy from an organ involved in disease. This standard approach not 3 
only can define a disease, but also can help determine optimal therapy and provide 4 
prognostic information. In a few instances, such as protocol biopsies in solid organ 5 
transplant settings, repeated histopathology evaluation can also be useful to evaluate 6 
response to therapy [1, 2]. With advancements in our understanding of molecular and 7 
cellular pathogenesis of several diseases, it has become apparent that the information 8 
obtained from a biopsy can be used to further individualize diagnosis and therapy; a 9 
process referred to as precision medicine. For instance, the presence of a specific 10 
cellular marker may imply a more aggressive disease and/or determine responsiveness 11 
to therapy. The field of oncology offers several illustrations where a form of precision 12 
medicine is already implemented in clinical use. For example, the adoption of specific 13 
tumor stains (estrogen receptor, human epidermal growth factor 2 receptor, HER2) [3-5] 14 
and gene expression profiling [6] to determine prognosis and shape therapy has now 15 
become a standard of care in the management of breast cancer.  16 
 17 
Before implementing a promising new tool on tissue specimens for clinical use, 18 
such a tool will require validation in preclinical models and testing of its utility in clinical 19 
studies. Because of the finite amount of the sampled tissue, especially in clinical 20 
settings, an ideal state-of-the-art tissue-interrogation technology should: 1) allow 21 
maximum extraction of the information from specimens of all sizes; 2) be amenable to 22 
standardization and reproducibility; 3) enable the production of quantitative analysis that 23 
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can be easily performed in non-specialized centers. The use of immuno-histochemical 1 
or immuno-fluorescence techniques to study protein expression in situ have been a 2 
cornerstone in clinical and research histopathology evaluation. Despite the widespread 3 
use of these techniques, the ability to translate quantitative observations into objective 4 
data points has been challenging. In addition to problems with reproducibility, the 5 
inherent bias from sampling a small area of tissue can be limiting. 6 
 7 
To address some of these limitations, several researchers have adopted the use 8 
of whole slide scanning to capture the entire area of available tissue and minimize 9 
sampling bias. In addition, many digital pathology software tools are being developed 10 
and implemented for use in clinical research studies. These tools may allow better 11 
standardization and objectivity. However, in the best-case scenario of optimal use, 12 
these technical advances still limit tissue examination in a 2-dimensional (2D) plane. A 13 
major shortcoming in such approach is the inability to capture the spatial characteristics 14 
and structures within complex organs.  For example, a glomerulus or an entire 15 
physiological unit of kidney, the nephron, extends the full depth of the kidney.  Further, 16 
complex cellular interactions, such as immune cells, do not limit their interactions to 2D 17 
planes.  In addition, when phenotyping cells using multiple labels, the uneven 18 
distribution of many cell surface markers reduces the accuracy of a simple 2D survey. 19 
Therefore, the characteristics of morphologically complex organs and the interactions 20 
between various types of cells in situ is better captured using three-dimensional (3D) 21 
imaging. 22 
 23 
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Recent development in optical sectioning microscopes have allowed researchers 1 
to  perform high resolution 3D microscopy at the millimeter scale in various tissues-2 
mesoscale imaging. With the implementation of multiple laser lines and methods of 3 
spectral unmixing, it is possible to characterize up to 8 different labels within tissue 4 
slices. Microscopy of this magnitude offers several advantages over conventional 5 
approaches to tissue histology: first, mesoscale images support the holistic interrogation 6 
of hundreds of thousands of cells, minimizing sampling bias and improving the detection 7 
of rare events;  second, mesoscale images capture tissue structures necessary to 8 
interpret pathology-the distribution of cells throughout the tissue and their possible 9 
activities; third, the characteristics of morphologically complex cells (such as neurons, 10 
dendritic cells, etc.) and their interactions can be captured. 11 
 12 
In this review, we will outline recent advances in mesoscale 3D imaging, its 13 
evolving methodology and discuss the available tools to perform quantitative analysis, 14 
and its potential applications in translational research1. The implementation of 15 
mesoscale multi-fluorescence 3D imaging and analysis will provide a powerful tool that 16 
allows unbiased high-resolution molecular and cellular mapping of tissue specimen in 17 
health and disease states.  18 
 19 
 20 
 21 
                                                 
1
 All data presented in this manuscript conform to the ethical guidelines for human and 
animal research and has been approved by the Indiana University Institutional Review 
Board and the Institutional Animal Care and Use Committee.   
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Enabling Technologies 1 
In the past 10 years, we have witnessed an explosion in the tools and technologies to 2 
enable mesoscale 3D imaging.  These advancements have included progress in tissue 3 
clearing and tissue staining, the availability of automated microscopes with rediscovered 4 
and new optical sectioning modalities, and the development of new analytical 5 
approaches.  The clinical setting imposes several restrictions on the adoption of new 6 
technologies including diagnostic value that can be delivered in a timely fashion for 7 
responsive interventions and efficient use of often limiting amounts of sample or tissue.  8 
Current practice in tissue section imaging includes immuno-fluorescence and small 9 
fluorescent-molecule staining to identify cellular markers and tissue structure.  As 3D 10 
mesoscale imaging is a volumetric extension of thin section imaging, it can rely on the 11 
multitude of antibodies and reagents developed for thin-section staining. 12 
Thus, the adoption of mesoscale 3D imaging for clinical application will require that 1) 13 
there be additional or improved information gained, such as more accurate and/or 14 
additional parameters for quantitation and diagnostics, 2) samples must be processed, 15 
imaged and quantified on the order of hours and days not weeks, 3) sample processing 16 
must be efficient, as human biopsy or tissue samples are available in limited amounts; 17 
approaches that are compatible with multiple rounds of analysis would be ideal, 4) 18 
sample processing must be compatible with existing practice (e.g. immunofluorescence, 19 
etc.) and not require expensive instrumentation or extraordinary expertise to use.  The 20 
additional information gained from 3D mesoscale imaging will enable the interrogation 21 
of hundreds of thousands of cells, the precise quantitation of spatial relationships in 3D 22 
and the potential to develop new models and parameters for diagnostics.  Thus, we 23 
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would argue that the translational potential of new tools, techniques and approaches for 1 
3D mesoscale imaging, hinges on speed, efficiency and compatibility with existing 2 
practice. 3 
  4 
Tissue Preparation 5 
Several methodologies can be used to prepare a tissue section for volumetric imaging. 6 
In its simplest form, a reasonably sized tissue is fixed using 4% paraformaldehyde 7 
immediately after harvesting, and subsequently sectioned using a vibrotome into slices 8 
of 50 to 100 µm thick [7-9]. This process applies to solid organ samples, such as the 9 
kidney, as we described previously. In our experience, a tissue section of 50 µm will 10 
allow uniform penetration and staining with antibodies and small molecules [7, 8, 10]. 11 
For small specimen or soft organs, tissue sectioning is only feasible after freezing with 12 
cryoprotection. This process also applies to small human specimens, such as core 13 
samples from a kidney biopsy. Additionally, we found that human biopsies preserved in 14 
Michel’s solution prior to freezing remain well suited for processing and fluorescence 3D 15 
imaging [10]. When imaging a large surface area like a section from a core biopsy (4-6 16 
mm2), the magnitude of data obtained from 50 µm sections is tremendous, >10 GB with 17 
multiple channels (Figure 1). However, it may also be necessary to image deeper into 18 
tissues, up to hundreds of microns and millimeters, to assess whole glomeruli or the 19 
entirety of a nephron[11].  This is now possible with advancements in tissue preparation 20 
and the use of “tissue clearing”. 21 
 22 
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The opaqueness of organs is due to inhomogeneous scattering of light in the tissue.  1 
This inhomogeneous scattering is a result of variation in refractive index (RI) in the 2 
tissue due to anatomical structure, different cell types in tissues, the variety in the 3 
organization of organelles in these cells and the RI differences between membranes, 4 
the cytosol and protein.  More than a hundred years ago, anatomists recognized the 5 
inhomogeneity could be minimized and began developing tissue clearing protocols[12, 6 
13].  The goal in tissue clearing is to remove this RI inhomogeneity.  When effective, 7 
tissue clearing uncovers mesoscale 3D structure from normally opaque tissue (Figure 2) 8 
[14-17].  9 
 10 
There are at least 18 unique approaches to clearing tissue (as reviewed in 11 
Richardson and Lichtman)[13].  These approaches have been developed for a variety of 12 
purposes including but not limited to clearing specific organs (i.e. brain), to stabilize 13 
membranes and lipid dyes or fluorescent proteins, or to be compatible with and extend 14 
existing staining protocols (i.e. immunofluorescence and repeated rounds of 15 
immunofluorescence).  Taking into consideration clinical restrictions as described 16 
above, we can focus on protocols with relatively short durations (within days vs. weeks), 17 
that support immunostaining.  This leaves ten of the eighteen techniques reviewed: 18 
iDISCO, BABB, Sucrose, FocusClear, ClearT2, CUBIC, Clarity, PARS, SWITCH and 19 
ACT-PRESTO[13].  Papers using BABB, Sucrose, FocusClear, ClearT2, CUBIC and 20 
iDISCO all demonstrate immunostaining.  iDISCO is unique in that it was specifically 21 
developed to support rapid immunostaining and clearing[18].  Pushing the state-of-the-22 
art, SWITCH is especially exciting as 20 successive rounds of immunostaining were 23 
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demonstrated on large volumes[19].  This is ideal for extracting the maximum amount of 1 
information from the limited amount of tissue provided by human biopsies.  While it is 2 
possible that other protocols based upon hydrogel embedding are also compatible with 3 
multiple rounds of immunostaining (e.g, Clarity, PARS, and ACT-PRESTO[20-23])  4 
adoption of these techniques is complicated by their reliance on specialized equipment 5 
and procedures for electrophoretic tissue clearing.  6 
  7 
While it is difficult to recommend a particular protocol, perhaps the best criterion 8 
is the degree to which a protocol has been adopted for research studies.  A non-9 
rigorous survey of the primary literature in PubMed demonstrates that the iDISCO and 10 
Clarity approaches are, to date, amongst the most widely applied when considering the 11 
number of years since publication.  The choice of technique will also depend upon the 12 
outcome of systematic validations in which results obtained from mesoscale analysis of 13 
cleared tissues are compared with those obtained from conventional pathology 14 
approaches.  These validations are critical as there is no guarantee that tissue or organ 15 
structure will not be altered by clearing, as tissue shrinkage[16] and tissue expansion 16 
and/or protein loss[20] have been observed. With clinical samples tissue clearing may 17 
be further complicated by the impact of different pathophysiology on a protocol’s 18 
efficacy.  It seems reasonable to assume that the best protocol will need to be 19 
empirically validated for different types of clinical samples[24].  20 
 21 
 22 
Staining and multispectral imaging 23 
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The ability to clear tissue is only useful if there are complimentary methods for labeling 1 
tissue structures of interest-including cellular and molecular markers.  Fortunately, there 2 
are well-established techniques for staining of tissue and thin sections with dyes and by 3 
immunofluorescence[25, 26].  The accessibility of antibodies to structures buried in the 4 
specimen is one of the major challenge in labeling thicker tissues. To circumvent this 5 
problem, small molecules can be used to label structures.  For instance, there are 6 
fluorescent toxins, nucleic acid binding dyes and sugar binding lectins for labeling cell-7 
surface proteins.   Some examples include, fluorescent-taxol for microtubules, 8 
fluorescent phallotoxins for filamentous actin (f-actin), DAPI ((4',6-diamidino-2-9 
phenylindole) which bind DNA and lectins for labeling sugar modified surface proteins.  10 
Vector Labs supplies kits that include a wide variety of fluorescently conjugated lectins 11 
that bind a variety sugar chains and can provide labeling of tissue structures. These 12 
small molecules have the advantage of size when staining large specimens.  A 13 
weakness of using some small molecule dyes are their dependence on specific 14 
structures that may be poorly preserved during fixation or damaged by tissue clearing.  15 
For instance, in our hands f-actin has proven difficult to stain with some aqueous tissue 16 
clearing protocols. As fluorescence-labeled phallotoxin binds between actin monomers 17 
in f-actin, we hypothesize that f-actin is labile in the protocols we’ve tried[27]. 18 
 19 
Immunofluorescence staining allows for a greater variety of specific and targeted 20 
labeling. Antibodies may bind to protein conformations or “discontinuous epitopes” or 21 
short peptide sequences[28].  Linear peptide antibodies may be less sensitive to tissue 22 
preparations that include denaturation of higher order protein structure[29, 30].  23 
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Unfortunately, due to their size, antibodies may have limited penetrance into tissue.  1 
Antibody protease digestions products, Fab and Fab2 fragment, may partially alleviate 2 
this size restriction.  More exciting, great potential exists in the application of naturally 3 
small antibodies or nanobodies[31].  Furthermore, mechanical and electrophoretic 4 
methods to increase the penetration and staining of the antibodies are being 5 
explored[19, 22, 32]. 6 
 7 
With standard multi-channel imaging on a laser scanning confocal 3-4 spectrally 8 
separable dyes can be imaged.  Starting with Alexa dyes (ThermoFisher), there has 9 
been an ever-growing repertoire of high quality fluorophores across the visible light 10 
spectrum with excitations tuned to the major laser excitation wavelengths of confocal 11 
microscopes.  Further, distinct emission wavelengths have enabled off-the-shelf four 12 
channel imaging on commercially available microscopes.  With linear unmixing multiple 13 
fluorophores can be combined with overlapping emission in an imaging experiment.  14 
This allows for the imaging up to eight markers in a sample (Figure 3 and 5).  Linear 15 
unmixing separates the contribution of single fluorophores in a multiple fluorophore 16 
labeled sample using a reference spectra(Figure 3, left panel)[33].  An exciting 17 
possibility is combining both spectral unmixing and a fluorophore’s fluorescent lifetime.  18 
Lifetime is a characteristic time that it takes a fluorophore to emit a photon after 19 
excitation.  If lifetimes are distinct, this information could be used to separate spectrally 20 
identical species, further increasing the number of molecular targets that could be 21 
imaged[34].  The use of multiphoton fluorescence lifetime imaging microscopy to image 22 
intrinsic fluorophores and metabolic state is also an interesting prospect[35-37].  For 23 
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instance, imaging intrinsic fluorophores with fluorescence lifetime imaging microscopy 1 
could provide a method for rapid assessment of clinical samples[38]. 2 
 3 
The degree to which cellular and molecular markers are present in specimens is 4 
going to be affected by both tissue preparation and underlying pathologies.  As tissue 5 
clearing can impact the availability of markers, staining with new reagents and new 6 
tissues will need to be validated experimentally.  Tissue preparation and staining is thus 7 
a careful balance between the homogenization of the RIs in a specimen while retaining 8 
the salient markers. 9 
 10 
Imaging Platforms 11 
One impetus driving research into tissue clarification has been the concomitant 12 
flourishing of optical sectioning microscopes that support three-dimensional imaging.  13 
Optical sectioning microscopes minimize out-of-plane fluorescence thereby increasing 14 
the contrast of the in-focus image[25, 39].  Optical sectioning microscopes have the 15 
advantage over serial sectioning approaches as the tissue is not destroyed in the 16 
process[40, 41].  This allows the sample to be restained or imaged by complementary 17 
approaches such as micro-computed tomography.  The confocal microscope is the 18 
workhorse of mesoscale high-resolution imaging and is commonly used to image large 19 
specimens[20-22, 42, 43].  Confocal microscopes, which are decades old in design, 20 
have become highly automated and easy to use and capable of scanning millimeter 21 
scale samples labeled with multiple fluorophores.  Further, spectral imaging is easily 22 
implemented and available on most commercial confocal microscopes. 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
 1 
An alternative approach to confocal microscopy is to use an optical sectioning 2 
microscope that only excites the imaging focal plane.  There are two approaches that 3 
accomplish this, 1) multiphoton excitation microscopy and 2) the many variations of 4 
light-sheet microscopy (LSM).  These modalities have advantages in 3D mesoscale 5 
imaging but they also have unique complications.  Multiphoton fluorescence microscopy 6 
depends upon the simultaneous absorption of two photons, which occurs only at the 7 
focus of the objective lens(Reviewed in [44]).  Primarily used to image deep into 8 
scattering biological tissues, multiphoton microscopy has also been used to image large 9 
cleared tissue at depth[14, 18, 45, 46].  Light sheet microscopy, like confocal 10 
microscopy, is a technology that was developed decades ago[47-49] (Reviewed in [50]).  11 
In its simplest form, LSM is based upon stimulation of fluorescence by a thin sheet of 12 
light, which is imaged by a camera placed orthogonal to the light sheet.  LSM’s major 13 
advantages are 1) its adaptability in imaging large specimens and 2) its speed 14 
(Reviewed in Power and Huisken, 2017)[51].  Recently, it has seen a resurgence in 15 
imaging naturally clear embryos [52, 53].  Over the past two and half decade’s light 16 
sheet microscopy has also been applied to imaging other large specimens such as 17 
cleared tissue and organs[15, 16, 18, 21-23, 43, 48, 54].  18 
 19 
Confocal microscopes are available from the four major manufacturers of 20 
microscopes, including Zeiss, Leica, Nikon and Olympus.  All can be configured for 21 
multiphoton excitation at additional cost of one to two hundred thousand dollars in laser 22 
and beam routing optics.  It should be noted that light sheet microscopes are also 23 
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commercially available from three manufacturers, Leica, Zeiss and LaVisionBiotec.  Of 1 
these, LaVisionBiotec’s, Ultramicroscope has been use in tissue clearing 2 
publications[15, 18, 55, 56].   3 
 4 
For the purposes discussed here, confocal microscopy has significant 5 
advantages over multiphoton and light sheet microscopy.  First, multiphoton and LSM 6 
are typically limited to no more than 4 or 5 different fluorophores, recent designs of 7 
confocal microscopes support imaging upwards of eight different probes. Second, 8 
confocal microscopy is also not limited to specific research groups with expertise in 9 
building and running microscopes, thanks to the abundance of commercial easy to use 10 
platforms. For instance, after a few hours of training a non-expert researcher can be 11 
imaging on these platforms.  12 
 13 
The combination of tissue clearing, fluorescence labeling of multiple markers 14 
(more than four or five) and imaging of large tissues and organs by confocal microscopy 15 
forms the pillars of a holistic approach to the analysis of millimeter scale specimens 16 
(Figure 2 and 5).  We can reasonably imagine applying these techniques to human 17 
samples and investigate key cellular players and structural changes in cancer biopsies, 18 
follow the progress of transplant rejection and examine and characterize tissue 19 
pathophysiology all in mesoscale 3D volumes.  Further, with appropriate vetting and 20 
validation, models of pathophysiology could be developed which may prove useful in a 21 
clinical setting.  Thus, the software tool(s) that enable researchers to develop such 22 
models could become central to defining the translation potential of this combination.   23 
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 1 
Exploring and analyzing mesoscale 3D volumes 2 
In general, any approach to analyzing mesoscale 3D volumes needs to be 1) robust and 3 
able to support large and complex datasets (Figure 2 and 5), 2) provide an intuitive 4 
bidirectional workflow integrating image processing to analysis with 3D visualization to 5 
facilitate discovery and 3) provide simple extensibility for testing and use of new 6 
methods of image processing and analysis (Figure 4B).  Currently tools available for 7 
analyzing mesoscale datasets fall into two broad categories, commercial and open 8 
source (Figure 4A).  Unfortunately, the number of tools that are specifically tailored to 9 
analyzing mesoscale 3D datasets is limited. In addition, the ability to perform 10 
meaningful analysis on large datasets frequently requires the combination of 11 
commercial and custom software whose cost and/or sophistication is beyond the reach 12 
of many biomedical researchers.  Fortunately, there are many active efforts to improve 13 
image analysis approaches in 3D, including solutions for visualization, segmentation 14 
and analysis[57-62].  As we discuss below, our own efforts have focused on combining 15 
efficient exploration and quantitative analysis of mesoscale 3D image datasets into a 16 
single platform that will provide wide accessibility of this powerful approach to the 17 
research community.  18 
  19 
Existing commercial software capable of 3D analysis are targeted towards 20 
research and/or image based high content screening systems for drug discovery.  No 21 
software or platforms has been designed specifically for mesoscale 3D image analysis.  22 
Research focused commercial packages include Amira(ThermoFisher), 23 
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MetaExpress/Metamorph (Molecular Devices), Imaris (Bitplane/Andor) and Volocity 1 
(Perkin-Elmer) are stalwarts in image processing and 3D visualization and analysis. 2 
These packages provide researchers with solutions for visualization and segmentation 3 
out-of-the-box.  Further, Imaris includes methods to facilitate the use of sophisticated 4 
image analysis tools via ImageJ/FIJI and MATLAB[59].  Although previously focused on 5 
research applications Perkin Elmer has extended Volocity to support its portfolio of 6 
imaging high content screening (IHCS) systems.  There are number of additional 7 
companies that are making IHCS systems including GE Lifesciences and 8 
Tissuegnostics.  Tissuegnostic’s TissueQuest software was the first to provide 9 
researchers with a tool that provided a flow cytometry like interface to analyze single 10 
cell phenotypes from 2D image data[63, 64].  Recently, both GE Lifesciences and 11 
TissueGnostics have brought to market confocal based IHCS systems to support 3D 12 
imaging.  Whether these novel systems will play a role in large-scale or mesoscale 3D 13 
imaging is yet to be seen.  Lastly, Definiens’ TissueStudio, ImageMiner and XD fill a 14 
unique role in the image processing software landscape.  Their software integrates 15 
segmentation tools, with a well-developed machine learning engine, “Cognition Network 16 
Technology” and the capacity for customization by the end user.  This customization will 17 
prove powerful.  For instance, being able to extend segmentation algorithms will make 18 
meeting the challenges of segmenting different nuclei possible (Figure 2 vs. Figure 5). 19 
 20 
The alternative to commercial software is the active community of open source 21 
and freeware software projects centered around ImageJ/FIJI and Icy [59, 65].  The 22 
absence of a financial barrier to use the software can make them easier for developers 23 
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and user to adopt.  Open source and freeware software can also facilitate the adoption 1 
of new techniques in a field, through extensibility, without the restrictions imposed by 2 
commercial solutions, including closed software or limiting license agreements.  A 3 
disadvantage of open source and freeware software is that on-going support of plugins 4 
and tools may be difficult with changing developers and interests. FIJI and Icy are both 5 
general purpose image processing applications that can be easily extended and 6 
improved by the community through plugins.  There are a handful of plugins that 7 
facilitate 3D image analysis (Figure 4A)[60, 66-68].  Beyond FIJI and Icy there are 8 
additional open source and/or freeware for 3D rendering including Vaa3D [57, 61, 62, 9 
69]. Vaa3D has also implemented a plugin architecture for image processing and 10 
analysis.  Although Vaa3D, FIJI and Icy may provide disparate tools required in image 11 
processing and some analysis tools, none of the software provides an easy to use 12 
bidirectional interface that integrates image processing, segmentation and exploration.   13 
 14 
We recently developed volumetric tissue exploration and analysis (VTEA) 15 
software in response to the need for an integrated and powerful, yet user-friendly, 16 
solution to analyze large 3D image volumes and mesoscale datasets of tissue[10].  17 
VTEA was designed around an intuitive interface with a bi-directional workflow to 18 
facilitate discovery and provide a framework for extensibility and reproducibility. The 19 
unique value of VTEA rests on the following features: 1) it requires mastery of a single 20 
software system, 2) the components are organized into an intuitive image analysis 21 
workflow accessible to researchers without expertise in image analysis, 3) the various 22 
components of the image and data analysis workflow are dynamically interlinked in a bi-23 
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directional workflow and 4) has been designed and will include extensible image 1 
processing, segmentation, visualization and data interrogation components.  VTEA is 2 
available for download via the FIJI updater as described at, https://imagej.net/VTEA. 3 
 4 
The uniqueness of VTEA is laid-out in Figure 4A. Software packages that can 5 
analyze 3D data are a mix of open source projects and commercial software.  Although 6 
some commercial software provides mechanisms for customization and addition of 7 
functionality-notably Imaris and Tissue Studio, they are expensive.  If we exclude these 8 
packages and focus on open source the remaining software include several general 9 
image analysis packages (Icy and FIJI) that may be full featured but require significant 10 
expertise to use[59, 65] or visualization software which may include some or limited 11 
image processing and object segmentation tools (FluoRender, BioImageXD and 12 
Vaa3D)[57, 61, 69].  The two remaining tools, VTEA and TANGO a FIJI plugin for 13 
analyzing nuclear organization, both integrate multiple aspects of image processing, 14 
segmentation and visualization into a workflow.  As such the user is not required to 15 
keep track of analyses, the processing, segmentation and objects and their associated 16 
measurements-the plugins do the bookkeeping.  Importantly, the various aspects of 17 
either tool are extensible to accommodate new techniques and approaches.  How VTEA 18 
differentiates itself from TANGO is the inclusion of quantitative visualization and 19 
analysis tools currently in the form of dynamically linked scatter plots and images.  This 20 
is in part due to the underlying intended utility of the two tools.  TANGO was developed 21 
to aid in identifying and characterizing nuclear morphology[67] and VTEA was 22 
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developed to aid in identifying, characterizing hundreds of thousands of cells and 1 
enable 3D tissue cytometry and exploratory analysis[10].  2 
 3 
Application of Large-scale quantitative 3D tissue imaging and analysis in research 4 
settings  5 
The ability to interrogate intact tissues by performing quantitative surveys of specific 6 
cells, based on a surface marker label, is an immediate application of this technology.  7 
This process, referred to as 3D tissue cytometry (3DTC) is the equivalent of performing 8 
flow cytometry to intact tissues, except that the spatial context is preserved, and no bias 9 
is introduced through tissue digestion and homogenization. 10 
 11 
Examples of such an approach applied on a limited-scale were demonstrated in 12 
the works of Gerner et al. [70] or Moreau et al. [71], who used multiple software 13 
packages in a complex analytical pipeline to distinguish and localize several immune 14 
cell populations in mouse tissue. Liarski and colleagues used a similar approach to 15 
measure distances between lymphocytes in human kidney biopsies [72]. Recently, we 16 
showed that the streamlined approach of VTEA can be easily used to characterize 17 
various resident immune cell populations in the mouse kidney [10]. Furthermore, we 18 
showed that VTEA analysis can be easily implemented on large-scale volumes, to 19 
quantitate immune cell distribution in entire thick sections of human kidney core 20 
biopsies. This approach is again demonstrated in Figure 5, where immune cell 21 
distribution using VTEA is shown in a nephrectomy thick section, imaged using a large-22 
scale confocal microscopy approach.  23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20
 1 
Because of the 3D nature of the datasets analyzed by VTEA, both the proportion of 2 
cells and their spatial density can be measured. This approach is implemented using a 3 
region-of-interest based analysis, where VTEA determines the density of specific 4 
immune cells in relation to specific structures. In an example from a human kidney 5 
biopsy (Figure 6), VTEA can distinguish a difference in the density of neutrophils around 6 
proximal tubules, based on a spatial parameter specific to these tubules. We also used 7 
this approach to measure dendritic cell clustering around glomeruli of mouse kidney 8 
[10]. Because measurements are normalized to the imaged volume, density-based 9 
measurements will extend the usefulness of VTEA by allowing comparisons not only 10 
within a specimen, and but also between different conditions or treatments. Through the 11 
extensibility feature in VTEA, the implementation of more complex, machine learning-12 
based algorithms (such as cell clustering and shape recognition) will further enhance 13 
the automation of analysis.  Furthermore, these algorithms will yield rich, “Big-data” 14 
style outputs for the hundreds of thousands of cells it already can classify. 15 
 16 
It is also important to emphasize that, because of the advances in intracellular 17 
labeling techniques, and the increasing repertoire of antibodies that can detect the 18 
activation of specific pathways, it is now possible to perform 3D quantitative analysis to 19 
determine specific pathway activation and signaling in a tissue. For example, through 20 
the specific detection of phosphorylated form of cJUN, VTEA can determine the 21 
activation of c-Jun-N-terminal kinase (JNK) signaling in a specific cell type (Figure 7). 22 
The functional quantitative data extracted from a tissue, complements the cytometry 23 
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analysis and provides a molecular context to studying tissue from a specific disease. 1 
We can envision the power and complexity of the data obtained from a tissue 2 
simultaneously probed for various cell and pathway activation markers, which will allow 3 
a precise determination of the cell type(s) activated in a disease process.    4 
 5 
Translational implications 6 
Although large-scale 3D quantitative imaging of tissue is not yet used in clinical 7 
applications, this approach is being implemented in various venues of translational and 8 
clinical research. We are using this approach to aid on-going clinical research by our 9 
group in the fields of kidney disease, urology and endocrinology.  We expect our 10 
approaches will be more widely applicable. Essential to the adoption of this approach 11 
are the availability of banked human tissue samples, and the development of a 12 
corresponding longitudinal clinical database.  In diabetes research, we are 13 
implementing large-scale 3D quantitative imaging on archived kidney biopsy tissue to 14 
understand the immune cell signatures of patients who progress to end stage renal 15 
disease. We are using a similar approach to understand the characteristics of human 16 
acute kidney injury, and identify patients who are at risk of progression to chronic kidney 17 
disease. Another example of application is in the field of human urolithiasis. Determining 18 
the different signatures of inflammatory cells in human kidney papillary biopsies for 19 
various type of kidney stones will unravel key pathways to understand the 20 
pathogenesis, and potentially offer a personalized approach for prevention and 21 
treatment of this heterogeneous disease. We envision a similar approach in 22 
characterizing tissue from other organs and diseases. For example, a better quantitative 23 
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approach for tumor markers within a biopsy can better characterize various types of 1 
cancer, and complement gene expression studies [6] to characterize prognosis and 2 
responsiveness to therapy.  3 
 4 
 5 
Concluding Remarks 6 
We are witnessing the dawn of a new era in tissue interrogation, through implementing 7 
important scientific advancements in the field, such as novel clearing techniques, 8 
multiple markers to identify subtypes of cells, large scale 3D imaging, and the use of 9 
innovative software, such as VTEA, for investigating and exploring mesoscale 3D 10 
imaging data. This synergistic approach will likely enhance our understanding of 11 
disease pathophysiology across organs, and facilitate the move to clinical application. In 12 
clinical studies, large-scale 3D quantitative imaging could be adapted to query human 13 
tissue biopsies at the molecular level, thereby providing a tool that could empower 14 
personalized medicine, especially when combined with genomics and transcriptomic 15 
data.  Undoubtedly, these efforts need to be expanded.  Furthermore, the application of 16 
novel 3D analytic methodologies to cellular and molecular pathology is still an evolving 17 
field.  Nevertheless, it is very likely that the observed progress in studying tissue 18 
specimens will adapt advancements in the fields of image processing and machine 19 
learning to unlock the third dimension of mesoscale 3D imaging.   20 
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Figure 1. Mosaic of 80 image volumes collected from a mouse kidney thick 1 
section.  A 50 µm section of mouse kidney was cut with a vibratome and stained for 2 
nuclei (DAPI,blue), F-actin (green), and with an antibody against MHCII (red).  Image 3 
volumes were collected using a 20X, NA 0.75 Leica objective on a Leica SP8 confocal 4 
microscope and mosaic merged in Fiji.  Image field is 6 mm across.  Inset – magnified 5 
region showing MHCII cells adjacent to two glomeruli. 6 
 7 
Figure 2. Tissue clearing and imaging of mesoscale 3D specimen generates 8 
complex, high resolution volumes.  Intestine from FLT3Cre+; ROSA26mTmG/mTmG 9 
mice expressing myristoylated-td-Tomato(myr td-Tomato, red) and GFP in myeloid 10 
cells(myeloid cells, green) were dissected, stained for nuclei(DAPI, gray) and cleared 11 
with Triton X-100 in phosphate buffered saline. Multiple overlapping volumes were 12 
imaged by confocal laser scanning microscopy and mosaic merged.  At left, DNA and 13 
GFP are shown to demonstrate the number and complexity of the enterocytes and 14 
intercalated myeloid cells. 15 
 16 
Figure 3. Spectral unmixing of seven labels in a human kidney biopsy volume.  17 
Beads and the biopsy were labeled with seven fluorophores. Multiple overlapping 18 
confocal volumes of the human biopsy were collected and mosaic merged.  Spectra 19 
from the independently labeled beads were used to spectrally unmix the seven 20 
fluorophores with LASX(Leica).  (A) Secondary antibodies independently absorbed to 21 
latex beads were combined and then spectrally unmixed with reference spectra.  22 
Reference spectra were collected from individually labeled beads.  (B) Human biopsies 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 34
were stained for nuclei (DAPI, gray), F-actin (phalloidin-Oregon Green 488, green) and 1 
species specific secondary antibodies labeled with Dylight594, Alexa647, Fluorescein, 2 
Alexa633 and Alexa568 were used to label primary antibodies against myeloperoxidase 3 
(MPO, red), macrophages (CD68, yellow), B-cells (CD45R, orange), Aquaporin-4 
1(AQP1, magenta) and Tamm-Horsfall Protein (THP, cyan).   5 
 6 
Figure 4.  Available tools with integrated 3D tissue cytometry workflow.  (A) VTEA 7 
provides the most comprehensive and easy-to-use open source tool for tissue 8 
cytometry.  (B)  VTEA was designed to support extensibility and a bidirectional 9 
workflow.  A bidirectional workflow supports and encourages an iterative refinement of 10 
image processing and segmentation to facilitate accurate quantitative analyses.  A 11 
common interface and workflow for tissue cytometry will enable reproducible user 12 
interaction and results.  Extensibility is available or planned for the three major 13 
components of VTEA: image processing, segmentation and analysis (visualization).  14 
This will allow for the incorporation of new approaches in the developing field of image 15 
processing and segmentation and to address new challenges. 16 
 17 
Figure 5.  Six channel 3D mesoscale imaging and analysis of a human 18 
nephrectomy section by tissue cytometry.  (A) Human nephrectomy was stained for 19 
nuclei (DAPI, gray), F-actin (phalloidin-Oregon Green 488, green), myeloperoxidase 20 
(MPO, red), macrophages (CD68, yellow), Aquaporin-1(AQP1, magenta) and Tamm-21 
Horsfall Protein (THP, cyan) and with species specific secondary antibodies labeled 22 
with Dylight594, Alexa647, Fluorescein, Alexa633 and Alexa568 respectively.  Multiple 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 35
overlapping volumes were imaged by confocal laser scanning microscopy, spectrally 1 
unmixed and mosaic merged. Spectral unmixing was performed with single fluorophore 2 
labeled beads as references.  (B) Merged and unmixed image was analyzed by VTEA 3 
and CD68 and MPO positive cells were quantified.  At right, gates were drawn on 4 
scatter plot in VTEA to identify CD68+ and MPO+ cells (yellow and red gates 5 
respectively).  Left, these cells were mapped to the original volume, a maximum 6 
projection is shown (as indicated in yellow, CD68+ and red, MPO+).  At lower right, a 7 
portion of the volume is rendered by Voxx in 3D with nuclei (gray), myeloperoxidase 8 
(MPO, red) and gated nuclei/cells (magenta).  Scale bar = 500 µm. This image was 9 
used with permission from the Journal of the American Society of Nephrology (Cover 10 
July 2017). 11 
 12 
Figure 6. Quantifying the spatial density of infiltrating neutrophils. 3D imaging and 13 
analysis of a biopsy stained for nuclei (DAPI, gray), F-actin (phalloidin,green) and 14 
myeloperoxidase (MPO, red). (A) Scatter plot showing all cells with their associated F-15 
actin and MPO staining. A gate for MPO positive cells is indicated by the yellow 16 
rectangle. (B) Representative 3D rendering with image data for DAPI, F-actin, MPO and 17 
an overlay (yellow) mapping the nuclei of MPO+ cells gated in A directly on the image 18 
volume. Proximal tubules (cyan arrowheads) and a glomerulus (G) are indicated. (C) 19 
Region-of-interest (ROI) interrogation of the image volume determines neutrophil 20 
density around different tubule segments. In this example, there was ten times more 21 
neutrophils around PT contiguous to a glomerulus (<100 µm distance) vs. non-22 
contiguous PT (ROI1 vs ROI2, respectively). Scale bar = 100 µm. 23 
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Figure 7. Kidney injury induced signaling quantified in 3D by tissue cytometry.  1 
(A)-Z-projection of a 50µm-thick image volume from the kidney of a mouse 6 hrs after 2 
ischemia-reperfusion injury, stained for DAPI (cyan), F-Actin (green) and p-c-Jun (red). 3 
(B) VTEA scatterplot of nucleated cells, with a gate (in yellow) for cells with nuclear 4 
(activated) c-Jun. (C) Volume rendering of panel A.   (D)  Volume rendering with gated 5 
cells as given in B, indicated in yellow. 6 
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